Unisec

UNISEC Scientific Presentations

 

2018

  • Microbiology Society conference, Birmingham April 2018 “Evaluation of the protective efficacy of an influenza DNA vaccine concept in the ferret model”
    (Kate Guilfoyle)
  • Anke Huckriede: Rational design of influenza vaccines 100 years after the Spanish Flu. Symposium PHD defence Eva van Doorn.
    January 2018 (Invited speaker).
  • Virology Seminar, Robert Koch-Institute. "Multiparametric Analysis of T-cell Responses to Vaccination: From the lab to clinical study analysis".
    Stephen Norley, February. 26th, 2018
  • 28th Annual Meeting of the Society for Virology, 14–17 March 2018, Würzburg, Germany "Induction of neutralizing and Fc-R activating antibodies against Influenza virus HA by immunization with AAV-vectors".
    D. Demminger, S. Norley, T. Wolff

 

2017 

  • 27th Annual Meeting of the Society for Virology, 22–25 March 2017, Marburg, Germany "Adeno-associated virus (AAV) vector as a vehicle for a broadly protective influenza vaccine".
    D. Demminger, S. Norley, T. Wolff
  • EDUFLUVAC Workshop, Brussels. "Multiparametric Analysis of T-cell Responses to Vaccination".
    Stephen Norley, 12th-13th June 2017
  • Anke Huckriede: Whole inactivated virus and subunit influenza vaccines: A world of difference. MYCOSYNVAC Vaccine Symposium: Vaccines at different levels of complexity from subunit to whole cell formulations, Nijmegen
    November 2017 (Oral presentation).
  • Anke Huckriede: Comparative influenza vaccine evaluation. EDUFLUVAC Workshop ‘Four years of European research on the development of universal influenza vaccines: what have we learnt and ho can we move forward? Brussels, Belgium
    June 2017 (Oral presentation).
  • Philip A. Born, Max Beugeling, Katie Amssoms,  Ben De Clerck, Ellen Van Gulck, Wouter L.J. Hinrichs, Henderik W. Frijlink, Niels Grasmeijer, Guenter Kraus, Roger Sutmuller, Kenny Simmen and Lieven Baert. 
    Influenza Vaccines for the World – IVW 2017 (Lausanne): Core-shell implants suitable to obtain a delayed IgG1 antibody response in mice (poster).
  • Yoshita Bhide: The cross-protective potential and the protection-relevant immune mechanisms of whole inactivated virus vaccines are determined by adjuvants and route of immunization. Influenza Vaccines for the World.
    April 2017 (Oral presentation).
  • World Vaccine Congress. Barcelona, Spain, October 2017.
    “Developing: universal vaccines against mosquito-transmitted diseases and against influenza” by SEEK
  • MVADS2017: Targeted delivery in rational vaccine design.
    Porto, Portugal, Sept. 2017.
  • Immuno Oncology Summit: Cancer Immunotherapy Based on Cross-Priming Liposomes CAF09.
    Boston MA, Aug. 2017.
  • Copenhagen workshop on injectables - Current and future challenges: Host-drug interaction - immune response in the local tissue.
    Copenhagen, Denmark, March 2017
  • Early cross-reactive T cell responses in tonsils after vaccination with LAIV in children.
    Mohn KGI, Brogstad K, Tøndel C, Aarstad HJ, Oftung F, Mjaaland S, Cox RJ.
    ESWI meeting Riga, Latvia, 2017.
  • Th1 and Th2 cytokine responses induced in humans by intranasal immunizations with an inactivated whole virus influenza vaccine.
    Fredrik Oftung, Gro Ellen Korsvold, Inger Lise Haugen, Carolyn Clark, Gro Tunheim, Johanna Bodin, Siri Mjaaland, and Bjørn Haneberg.
    ESWI meeting Riga, Latvia, 2017
  • ESWI meeting Riga 2017 Balanced Th1 and Th2 cytokine responses may be induced in humans by intranasal immunizations with an inactivated whole virus influenza vaccine. 
    Fredrik Oftung, Gro Ellen Korsvold, Inger Lise Haugen, Carolyn Clark, Gro Tunheim, Johanna Bodin, Siri Mjaaland, and Bjørn Haneberg.
  • Valentina Bernasconi (oral presentation) Global Vaccine and Vaccination Summit,
    Toronto, Canada.
    Nanoparticle-based mucosal vaccine adjuvant vectors against pandemic influenza infection
  • Ajibola Omokanye (oral presentation) 2017 ISV Annual Congress, Paris, France.
    M2e-specific memory CD4 T cells are multifunctional and protect against influenza A virus infection

 

2016

  • Anke Huckriede: Universal influenza vaccines – Old challenges and new approaches. International course ‘Vaccines for next generation’.
    Gothenburg, Sweden, April 2016 (Invited lecture).
  • Health and well-being conference: Teaching your immunesystem to eliminate cells heading down the wrong path – The construction of a cancer vaccine.
    Nottingham. England, May 2016.
  • Savic M, Dembinski JL, Laak I, Waalen K, Hungnes O, Cox R, Håberg S, Oftung F, Trogstad L, Mjaaland S. Cellular correlates to protection against A(H1N1)09 pandemic influenza during pregnancy Options for the control of influenza.
    Chicago 2016
  • J. Tomar. Pharmacy Day 2016 (Groningen, Netherlands):
    Influence of Advax adjuvant on the immune response of mucosally delivered influenza vaccine (Oral)
  • 5th International Influenza Meeting. Münster, Germany.
    Bhide Y. Comparative evaluation of universal influenza vaccine candidates. Oral presentation. 15 September
  • J. Tomar. Biopharmacy Day 2016 (Utrecht, Netherlands):
    Advax, a mucosal adjuvant for whole inactivated influenza vaccine (Oral)
  • J. Tomar. Mucosal Vaccines, Adjuvants and Delivery 2016 (Lausanne, Switzerland):
    Advax augments B and T cell responses upon influenza vaccination via the respiratory tract (Oral ppt)
  • P.A. Born. Pharmacy day 2016 (Groningen):
    Antigen-Adjuvant Interaction in an Influenza Vaccine Formulation (oral presentation).
  • Anke Huckriede: Head-to-head comparison of liposome- and protein-based adjuvants combined with whole inactivated influenza virus vaccines for induction of cross-reactive immunity in mice. Options for the Control of Influenza.
    Chicago, USA, August 2016 (Poster).
  • Anke Huckriede: Cotton rats as animal model for influenza infection and influenza vaccine evaluation. EDUFLUVAC Workshop ‘Experimental animal models for universal influenza vaccines.
    Rijswijk, Netherlands, June 2016 (Invited lecture).
  • Yoshita Bhide: Head-to-head comparison of liposome and protein based adjuvants combined with whole inactivated influenza virus vaccines (WIV) for induction of cross-reactive immunity in mice.
    Annual Vaccine Symposium, Utrecht, Netherlands, September 2016 (Oral presentation).
  • Anke Huckriede: Facilitating influenza vaccine development: In vitro DC models and comparative vaccine evaluation.
    Intravacc, Bilthoven, Netherlands, October 2016 (Invited lecture).
  • POSTER ViFU: Needle free intradermal delivery of a polyvalent influenza DNA vaccine induces cross-reactive humoral and cellular immune responses in pigs.
    Anders Fomsgaarda,b, Marie Borggrena, Jens Nielsena, Ingrid Karlssona and James A. Williamsc ISV, Boston, USA, 1-3 October2016
  • ORAL ViFU:Cellular and humoral immune responses in pigs after needle-free intradermal influenza DNA vaccination.
    Ingrid Karlssona, Marie Borggrena, Jens Nielsena, James A. Williamsc and Anders Fomsgaarda,b Cytometrie 2016, Montpellier, France, 8-10 November, 2016
  • 11th annual IMVACS Summit: Cationic ADJUVANT FORMULATION NO 1. CAF01 - Mode of Action and Potential for Vaccination Strategies Targeting the Mucosa.
    Boston MA, Dec. 7-9, 2016
  • 17th WVC: How physico-chemical properties of liposomes, emulsions, antigens and route of delivery can influence the immunological outcome.
    Barcelona, Spain, October 2016.
  • 7th APS International PharmSci Conference: Designing delivery systems for next generation vaccines.
    Glasgow, Scotland, Sept. 2016.
  • MVAF 2016: MoA of liposomal vaccine delivery systems.
    Copenhagen, DK, May 2016.
  • Cellular correlates of protection  against pandemic influenza during pregnancy.
    Miloje Savic, Jennifer L. Dembinski, Ida Laake, Olav Hungnes, Rebecca Cox, Fredrik Oftung, Lill Trogstad, Siri Mjaaland.
    Options for influenza Control, Chicago, USA 2016.
  • Standardized CMI and Ab analysis to assess immunogenicity of epitope based universal influenza vaccines tested in clinical phase II trials with and without HA vaccine based boosting. 
    H Liu, O Pleguezuelos, T Ben-Yedidia, E van Doorn, G Stoloff, S Hassin, R Babecoff, E Schmidt, A Huckriede, I Visontai, S. Norley, GE Korsvold, K Waalen, O Hungnes, LM Næss, S Mjaaland, F Oftung, E Hak.
    Network Conference for Influenza Vaccine Reserach in Norway, 2016.
  • Network for Influenza Vaccine Reserach in Norway, Finse 2016 Standardized CMI and Ab analysis to assess immunogenicity of epitope based universal influenza vaccines tested in clinical phase II trials with and without HA vaccine based boosting. H Liu, O Pleguezuelos, T Ben-Yedidia, E van Doorn, G Stoloff, S Hassin, R Babecoff, E Schmidt, A Huckriede, I Visontai, S. Norley, GE Korsvold, K Waalen, O Hungnes, LM Næss, S Mjaaland, F Oftung, E Hak
  • Options for Influenza Control, Chicago 2016 Functionally distinct T and NK cell populations may serve as immune correlates of protection against symptomatic pandemic influenza A(H1N1) virus infection during pregnancyMiloje Savic, Jennifer L. Dembinski, Ida Laake, Olav Hungnes, Rebecca Cox, Fredrik Oftung, Lill Trogstad , Siri Mjaaland
  • Virology Seminar, Robert Koch-Institute. "Development of a vector-based broadly-reactive Influenza vaccine".
    Feb. 15th, 2016, Daniel Demminger
  • Developing a broadly protective nanoparticle vaccine against influenza. Bernasconi V et al. 
    Oral presentation at the 5th International  Influenza Meeting, 26-28 September 2016 in Münster, Germany
  • 26th Annual Meeting of the Society for Virology, 06-09 April  in Münster, Germany
    Demminger D., Norley, S. and T. Wolff. Evaluation of Adeno-associated Virus (AAV)-Vector as a vehicle for a universal influenza vaccine. Oral presentation
  • 26th Annual Meeting of the Society for Virology, 6–9 April 2016, Munster, Germany. Oral presentation,  "Adeno-associated virus vector as a vehicle for a universal influenza vaccine"
    D. Demminger, T. Wolff
  • UNISEC Annual Meeting, Berlin, 18th-20th May, 2016. "Evaluation of the highly conserved influenza nucleoprotein as target antigen for AAV-based universal vaccines"
    Katharina Fiddeke, 18th-20th May, 2016
  • Virology Seminar, Robert Koch-Institute. "Evaluation of the highly conserved influenza nucleoprotein as target antigen for AAV-based universal vaccines".
    Katharina Fiddeke, Sept. 12th, 2016
  • Annual joint meeting of the K.G. Jebsen Center for Influenza Vaccine Research in Norway UNISEC: Standardized CMI and Ab analysis to assess immunogenicity of epitope based universal influenza vaccines tested in clinical phase II trials with and without HA based boosting.
    H Liu, O Pleguezuelos, T Ben-Yedidia, E van Doorn, G Stoloff, S Hassin, R Babecoff, E Schmidt, A Huckriede, I Visontai, S. Norley, GE Korsvold, K Waalen, O Hungnes, LM Næss, S Mjaaland, F Oftung, E Hak. Abstract, poster, and oral presentation
  • Vaccine Working Party Meeting, European Medical Agency, London. "Multiparametric Analysis of T-cell Responses".
    Stephen Norley, 23rd November, 2016
  • 26th Annual Meeting of the Society for Virology, 6–9 April 2016, Munster, Germany "Generation of a broadly-protective AAV-based influenza vaccine"
    K. Fiddeke, I. Sipo, M. Budt, T. Wolff, N. Bannert, S. Norley
  • Cellular correlates of protection against A(H1N1)pdm09 pandemic influenza during pregnancy.
    Miloje Savic, Jennifer L. Dembinski, Ida Laake, Kristian Waalen, Olav Hungnes, Rebecca Cox, Siri Håberg, Fredrik Oftung, Lill Trogstad, Siri Mjaaland. Abstract and poster presentation Options for Control of Influenza (ISIRV) Chicago, USA
  • 5th International  Influenza Meeting, 26-28 September 2016 in Münster, Germany. Omokanye A et al , Lung resident CD4 T cells protect against heterosubtypic influenza virus challenge. Oral presentation
  • Ajibola Omokanye (poster) 10th European Mucosal Immunology Group Meeting (EMIG), Copenhagen.
    Development of a universal influenza vaccine based on the CTA1-DD adjuvant vector
  • Ajibola Omokanye (oral presentation) 5th International Influenza Meeting, Münster.
    M2e-specific memory CD4 T cells are multifunctional and protect against influenza A virus infection
  • Valentina Bernasconi (oral presentation) 5th International Influenza Meeting, Münster.
    Porous nanoparticles for the mucosal delivery of an adjuvanted universal influenza vaccine.
  • Valentina Bernasconi (oral presentation). Virus-like particle & Nano-particle vaccines VLPNV 2016, Leiden Netherlands.
    A non-toxic formulation of CTA1-3M2e-DD in lipidic nanoparticles for improved mucosal immunization against influenza virus

 

2015

  • Influenza vaccines: Old challenges and new approaches. Invited speaker at meeting of Leiden Amsterdam Centre for Drug Research. Leiden, Netherlands, November 2015
    By Prof. Anke Huckriede UMCG
  • Universal influenza vaccines: Old challenges and new approaches. Invited speaker at vaccinology course, University of Gothenburg, Sweden April 2016
    By Prof. Anke Huckriede UMCG
  • Poster presentation at 25th Annual Meeting of the Society for Virology, 18-21 March 2015 in Bochum, Germany
    Fiddeke K, Sipo I, Norley S, Wolff T, Budt M, Bannert N. Generation of a Universal AAV-Based Influenza Vaccine.
  • POSTER: ”Polyvalent influenza-A DNA vaccine for pigs using needle-free intradermal delivery” Marie Borggren, Jens Nielsen, Ingrid Karlsson, Tina S. Dalgaard, Jim Williams, Anders Fomsgaard
    Influenza Vaccines for the World – IVW 2015 6-9 October2015, Portugal
  • INVITED ORAL: Anders Fomsgaard: ”Polyvalent influenza-A DNA vaccine for pigs and humans”. Anders Fomsgaard, Marie Borggren, Jens Nielsen, Ingrid Karlsson, Jim Williams.
    9th Vaccine & ISV Congress, 18-20 October2015, Seoul Korea.
  • The Society for Experimental Biology, Prague, June 30th – 3rd July Prof John Oxford has given the ‘Cell Biology Plenary Lecture’.
    The topic ‘Universal Influenza Vaccines’ and the EU consortium has been part of the presentation.
  • Dry powder vaccines as a stable, effective and convenient alternative to parenteral influenza vaccines
    Oral presentation congress ‘Influenza Vaccines for the World’, Albufeira, Portugal, October 2015
    By Prof. Anke Huckriede UMCG
  • EDUFLUVAC Workshop on Immunoassay Standardisation for Universal Flu Vaccines, NIBSC, Potters Bar. "Intracellular Cytokine Staining (ICS) Assay".
    Stephen Norley, 18th-19th June 2015
  • 25th Annual Meeting of the Society for Virology, 18-21 March 2015, Bochum, Germany "Generation of a broadly-protective AAV-based influenza vaccine" K. Fiddeke, I. Sipo, M. Budt, T. Wolff, N. Bannert, S. Norley
  • J. Tomar. Influenza Vaccines for the World – IVW 2015 (Albufeira, Portugal):
    Investigating the deposition site of influenza vaccine formulations in cotton rats(poster)
  • J. Tomar. Pharmacy Day 2015 (Groningen, Netherlands):
    Targeting vaccines to different regions of the respiratory tract: influence on immune responses (Oral)
  • Biopharmacy Day 2015 (Leuven, Belgium):
    Investigation the deposition site of influenza vaccine formulations in cotton rats (poster)
  • P.A. Born, A. Aliyandi, D. Christensen, N. Y. Lycke, W.L.J. Hinrichs, H.W. Frijlink.
    Influenza Vaccines for the World – IVW 2015 (Albufeira): The interactions between an antigen and adjuvant in influenza vaccine formulations (poster). 
  • P.A. Born. Foliolum March 2015:
    Een inhaleerbaar universeel griepvaccin: het einde van de (jaarlijkse) griepprik? (editorial local pharmacy magazine)
  • P.A. Born, A. Aliyandi, D. Christensen, N. Y. Lycke, W.L.J. Hinrichs, H.W. Frijlink.
    Biopharmacy day 2015 (Leuven): The interactions between an antigen and adjuvant in influenza vaccine formulations (poster).
  • Yoshita Bhide: Head-to-head comparison of liposome and protein based adjuvants combined with whole inactivated influenza virus vaccines (WIV) for induction of cross-reactive immunity in mice.
    Influenza Vaccines for the World. Albufeira, Portugal, October 2015 (Poster).
  • Anke Huckriede: Influenza vaccines – Old challenges and new approaches.
    Science Day Leiden Amsterdam Center for Drug Research.  Leiden, Netherlands, November 2015 (Invited lecture).
  • POSTER: ”Needle-free intradermal delivery of a broad polyvalent influenza-A DNA vaccine“
    Anders Fomsgaard, Marie Borggren, Jens Nielsen, Ingrid Karlsson, Jim Williams
    Skin Vaccination Summit 2015, Sept 2-4, 2015, Lausanne Switzerland
  • 26th National Immunisation Conference for Health Care Workers: Adjuvants – how they function in vaccines.
    Manchester, England, Dec. 2015.
  • 42nd CRS Annual Meeting and Exposition 2015: Vaccine delivery – depot or not?
    Edinburgh, Scotland, July 2015.
  • MVADS 2015: Tailoring vaccination for systemic and local Immune responses.
    Leiden, Holland, May 2015.
  • Vaccine Development Congress: Tailoring novel vaccine adjuvants for systemic and local Immune responses.
    Izmir, Turkey, April 2015.
  • DFSTM Spring Symposium 2015: Adjuvants: From immunologist’s dirty little secret to vaccinologist’s requisite for success.
    Copenhagen, Denmark. March 2015.
  • Virology Seminar, Robert Koch-Institute. "Standardised measurement and analysis of T-cell responses in human clinical trials of universal influenza vaccines".
    Stephen Norley, 22nd June, 2015
  • Innovative Task Force Meeting, European Medical Agency, London. "UNISEC Workpackage 5: Correlates of Protection".
    Stephen Norley, 17th June, 2015
  • 14th workshop on immunology of virus infection (German Society for Virology, GFV)
    Okt. 21-23 2015, Deidesheim, Germany “Evaluation of Adeno-associated Virus-Vector as a vehicle for a universal influenza vaccine”, Daniel Demminger
  • Ajibola Omokanye (oral presentation), 5th International Conference “Influenza Vaccines for the World” Development of a universal influenza vaccine based on the CTA1-DD adjuvant vector

 

2014

  • European Universal Influenza Vaccine UNISEC project. ISPE congress Taiwan
    By Prof. Eelko Hak, RUG The Netherlands
    Universal flu vaccine and pandemic preparedness AHEAD of outbreak
  • WHO meeting: the second W?HO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses. by dr. Tammy Ben-Yedidia, BiondVax, Israel
  • Influenza Vaccines of the Futures. Hungarian Society for Microbiology
    by Prof. Ildiko Visontai, NCE Hungary
  • Philip A. Born. Pharmacy day 2014 (Groningen): Lifelong influenza protection- a universal vaccine (oral presentation).
  • Oral: Fomsgaard A. “Easy needle-free intradermal delivery and vector optimization of a broad protective polyvalent influenza-A DNA vaccine for pigs”.
    The 10th Smögen Summer Symposium on Virology. Swedish Society for Virology, 21-23 August, 2014, Smögen, Sweden.
  • Oral: Fomsgaard A. “Needle-free intradermal delivery and vector optimization of a broad protective polyvalent influenza-A DNA vaccine for pigs and humans. International Society of DNA vaccines. DNA Vaccines 2014.
    San Diego 21-23 July, 2014.
  • Keystone Symposia, The Modes of Action of Vaccine Adjuvants: Vaccine formulation with liposome based adjuvants.
    Seattle, WA USA. Oct. 2014.
  • IMV 2014: Cellular targeting of immunostimulators.
    Algarve, Portugal. May 2014.
  • IMV 2014: CAF01: A safe and effective liposome adjuvant that promotes strong and long-lived antigen specific T cell responses in humans.
    Algarve, Portugal. May 2014.
  • Searching for a universal biomarker of human T cell responses to Influenza A virus infections. Jennifer L Dembinski, Fredrik Oftung, Miloje Savic, Yohan Kim, Bjoern Peters, Siri Mjaaland. ESWI meeting Riga, Latvia 2014.
  • Functionally distinct T and NK cell populations may serve as immune correlates of protection against symptomatic pandemic influenza A(H1N1) virus infection during pregnancy.
    Miloje Savic, Jennifer L. Dembinski, Ida Laake, Olav Hungnes, Rebecca Cox, Fredrik Oftung, Lill Trogstad, Siri Mjaaland.
    ESWI meeting Riga, Latvia 2014.
  • Design of randomized, double-blind, controlled, multi-center phase IIb trials as part of the EU-funded UNISEC project to assess the safety, immunogenicity and clinical efficacy of cross-seasonal universal influenza vaccines with or without pandemic influenza vaccine in healthy adults. Abstract presentation at Immunopotentiators in Modern Vaccines (IMV) conference. at 7-9 May 2014 in Portugal.
    By Prof. Eelko Hak, RUG The Netherlands

 

2013

 

  • ILS 2013: Designing a liposomal adjuvant for the induction of CD8+ T cells through targeted delivery to specialised dendritic cell populations.
    London, UK. Dec. 2013.
  • 19. VIC Congress 2013: Adjuvants: From alchemy to rational vaccine design (invited).
    Brussels, Belgium. Dec. 2013.
  • UNISEC (EU): Development of universal influenza vaccines. Oftung F and consortium partners: RUG, UMCG, NIBSC, SSI, RKI, hVIVO, BVX, SEEK, NIPH, NCE, UGOT.
    Network Conference for Influenza Vaccine Reserach in Norway, 2013.